"Matching the Market": Why the Payer Mix That Wins in 2026 Doesn't Avoid Medicare Advantage
Medicare Advantage is too large for most home health owners to ignore, but accepting every contract is not a strategy. Choice Health at Home’s “match the market” approach shows how operators can participate in MA while remaining disciplined about reimbursement, authorization burden, and clinical care. MedPAC’s 2026 data adds nuance by showing no statistically significant average margin impact, while highlighting greater pressure on smaller agencies. For owners considering a sale or succession, the priority is clear: make payer performance measurable, explainable, and durable before a buyer underwrites the business.
8/10/20268 min read
Medicare Advantage has surpassed traditional Medicare in the home health sector, forcing owners to rethink how they contract, staff, and prepare for a future sale. This article explains why Choice Health at Home’s “match the market” strategy offers a practical middle path for home health or hospice owners facing payer friction without abandoning growth.
Quick-Scan Summary
Who this is for
Home health or hospice owners generating $2 million to $10 million in annual revenue
Operators managing rising Medicare Advantage volume, prior authorization, and denial activity
Founders considering a sale, succession, or strategic partnership
Owners who want to improve buyer underwriting and protect sale price
Key takeaways
Avoiding Medicare Advantage is increasingly difficult as MA enrollment exceeds traditional Medicare in many home health markets.
Serving every MA plan without examining rates, authorization burden, and net margin is equally risky.
Choice Health at Home’s approach is to “match the market.” If local MA penetration is 50%, the company aims for approximately 50% MA patients.
MedPAC found no statistically significant association between market level MA penetration and home health agencies’ all payer margins on average.
Smaller agencies face greater financial pressure because administrative costs and contracting problems consume a larger share of their operating base.
Buyers will underwrite payer mix through effective reimbursement, administrative burden, referral stability, compliance, and EBITDA quality.
Medicare Advantage Has Changed the Home Health Operating Model
In 2026, Medicare Advantage is no longer a secondary payer issue for many home health operators. MA enrollment has surpassed traditional Medicare among beneficiaries receiving home health services, and the shift is visible in referral patterns, authorization workflows, and revenue cycle management.
The change creates a difficult operating reality. Traditional Medicare generally pays home health agencies through a prospective payment structure. MA plans may use per visit rates, episode rates, prior authorization, utilization review, and plan specific documentation requirements. Two patients with similar clinical needs can therefore create very different financial results depending on their payer.
The CY 2026 Home Health PPS Final Rule also reminded owners that positive rate updates do not necessarily translate into positive cash flow. CMS finalized a 2.4% payment update, but permanent and temporary adjustments resulted in an estimated 1.3% aggregate payment decrease for 2026.
The proposed outlook for 2027 is more positive. CMS estimates a 2.4% aggregate increase, or approximately $420 million, for home health agencies if the proposal is finalized. That shift improves the narrative, but it does not eliminate payer specific risk.
The Friction Is Real, Especially for Smaller Agencies
Home health or hospice clinicians often become the first line of defense when an MA plan disagrees with the number or type of visits a patient needs. A nurse may believe that another skilled visit is clinically necessary, while the plan says the patient has reached its authorized limit.
That creates three problems:
Patient care friction: Clinicians must spend time advocating for medically necessary services.
Administrative cost: Staff must manage authorizations, denials, peer to peer reviews, and appeals.
Financial uncertainty: Revenue depends on both the contract rate and the amount of care the plan ultimately approves.
In its June 2026 report, MedPAC reported that home health agency representatives consistently identified higher administrative costs related to authorization and appeals. Interviewees also reported that MA plans often paid lower per visit rates than traditional Medicare, although payment structures varied.
The burden is usually more pronounced for smaller agencies. A large platform can spread authorization staff, compliance systems, contracting expertise, and technology investments across multiple branches. A $3 million agency may have to absorb the same payer complexity with one billing manager and a small clinical leadership team.
An anonymized example illustrates the issue. One regional home health owner had strong referral relationships and a stable census, but nearly 40% of revenue came from two MA plans. The agency was busy, yet its owner could not explain its net margin by plan. A buyer would not simply see “40% MA.” The buyer would examine authorization hours, denied visits, appeal outcomes, average payment per completed visit, and the resulting EBITDA.
Choice Health at Home’s Middle Path: “Match the Market”
Choice Health at Home provides a useful case study. Based in Tyler, Texas, and operating across nine states, Choice has built a three pronged service foundation across home health, hospice, and personal care.
In a 2026 interview with Home Health Care News, CEO David Jackson rejected the idea of simply refusing MA patients. He said, “We think it is somewhat foolish to stick your head in the sand and say, ‘Hey, we’re just not going to treat those patients.’”
Choice’s strategy is straightforward: match the market. If 50% of Medicare beneficiaries in a region are enrolled in MA, Choice strives to serve approximately 50% MA patients in that market.
This is not the same as signing every contract. It means accepting that payer mix should reflect the market while remaining selective about contract terms, operational burden, and clinical fit.
Choice has completed 53 acquisitions, including 24 since 2020, and uses a hub and spoke density model. The company builds scale in major markets before extending into surrounding communities. That model matters because density can support centralized authorization, billing, compliance, and clinical oversight.
Jackson also said the enrollment moratorium would not necessarily slow larger buyers. “We’ll buy license numbers, buy established businesses; we’re going to look at compliance right out of the gate.” For owners, the message is direct: compliance readiness and payer discipline will influence buyer interest even when the broader market remains active.
What MedPAC’s Margin Data Really Says
The Medicare Payment Advisory Commission’s June 2026 analysis provides important balance to the MA debate.
From 2013 to 2024, median MA penetration in home health agency markets increased from 29% to 58%. Over that period, median home health all payer revenue increased from $2.0 million to $2.4 million, while the median all payer margin increased from 3.2% to 4.9%.
MedPAC estimated that a 10 percentage point increase in market level MA penetration was associated with:
A 2.7% decline in all payer revenue
A 2.7% decline in all payer costs
A 0.12 percentage point decline in all payer margin, which was not statistically significant
No statistically significant decline in total visits or patients
The conclusion is not that MA is harmless for every agency. MedPAC specifically noted that individual providers can experience meaningful effects. The national average simply does not show a statistically significant margin impact across all agencies.
The analysis also found greater revenue, cost, and volume pressure among smaller home health agencies. That finding supports an operator focused conclusion: scale and process discipline may determine whether an agency can absorb MA complexity without damaging EBITDA.
Payer Mix Strategy and Valuation Math
A buyer does not underwrite payer mix as a simple percentage. The buyer underwrites the quality and durability of the cash flow produced by that mix.
Consider two hypothetical home health agencies:
The difference is approximately $937,500. This is an illustrative underwriting scenario, not a published market multiple. The point is that two agencies with identical revenue and EBITDA can receive different valuations when one has more predictable reimbursement, cleaner payer reporting, and lower administrative risk.
The opposite can also be true. An agency with 55% MA revenue may be more attractive than an agency with 20% MA revenue if the higher MA agency has strong contracts, low denial rates, efficient authorization workflows, and a payer mix aligned with local market demand.
Track these metrics monthly:
Net reimbursement per completed visit by payer
Authorized visits compared with clinically ordered visits
Denials and appeal overturn rates
Authorization labor hours per 100 MA episodes
Days in accounts receivable by payer
EBITDA margin by payer
Revenue concentration by individual MA plan
Referral volume by payer and referral source
For a broader view of buyer underwriting, focus on valuation drivers such as reimbursement quality, payer concentration, authorization burden, compliance readiness, and EBITDA durability
What This Means for Hospice Owners
Hospice owners should not assume that a home health payer strategy transfers directly to hospice. The Medicare Hospice Benefit has its own payment structure, compliance requirements, election rules, and length of stay considerations.
The parallel lesson is operational. Hospice buyers will still examine referral concentration, payer exposure, documentation, staffing stability, compliance history, and the ability to produce reliable EBITDA without excessive founder involvement.
An anonymized hospice owner may have limited direct MA contracting exposure but still face payer related valuation risk through managed care referrals, hospital relationships, and changing referral patterns. The buyer will want to understand where patients originate, how contracts influence admissions, and whether the agency can maintain quality while referral channels change.
Exit Timing: Do Not Wait for Perfect Payer Conditions
There may never be a perfect payer environment. Waiting until every MA contract is renegotiated can create its own risk, especially if the owner is burned out, a key clinical leader may leave, or succession has not been documented.
A better approach is to measure readiness:
Can you produce payer level revenue and EBITDA reports?
Can you explain why MA margins differ from traditional Medicare margins?
Are your top contracts profitable after authorization labor?
Is any single payer responsible for an outsized share of revenue?
Can the agency operate if the founder steps away?
Are compliance records, licenses, surveys, and corrective actions organized?
Senate Healthcare’s home health or hospice transition perspective is owner to buyer. We evaluate agencies based on clinical foundation, compliance, operational durability, and the opportunity to build sustainable care across the communities they serve.
So what should you do now?
Measure your local market: Compare your MA percentage with local enrollment, not a national average. A practical starting point is to investigate any gap of more than 10 percentage points between your payer mix and the market.
Underwrite each contract: Review net payment, authorization time, denial rates, appeal outcomes, and contribution margin by payer.
Protect sale value: Build clean monthly reporting that separates payer revenue, direct labor, authorization expense, and EBITDA.
Prepare before a transition: Reduce key person dependence, organize compliance records, and identify which contracts a buyer would retain, renegotiate, or exit.
Senate Healthcare is the buyer and strategic partner pursuing acquisitions of home health or hospice agencies. If you are considering a sale, succession, or partnership, connect with Senate Healthcare for a confidential conversation about your agency, your payer mix, and your desired outcome. You do not need to be perfectly positioned today. We are evaluating agencies with different strengths and readiness levels, with the goal of reducing transition risk while preserving quality care and owner value.
Plain-Language Glossary
Medicare Advantage: Private Medicare health plans that receive payments from CMS to provide covered Medicare benefits.
Traditional Medicare or FFS: Original Medicare, where providers are generally paid under federal fee for service rules.
Payer mix: The percentage of an agency’s revenue generated by each payer.
Prior authorization: Approval a health plan requires before it will pay for certain services.
All payer margin: Profit after costs across all payers, not just one insurance program.
EBITDA: A measure of operating profit before interest, taxes, depreciation, and amortization.
Buyer underwriting: The process a buyer uses to evaluate revenue quality, risk, profitability, and future cash flow.
Valuation multiple: The number multiplied by EBITDA to estimate enterprise value. A 6.0x multiple on $750,000 of EBITDA equals $4.5 million.
Unlock Your 30-Minute Agency Succession Review
Maybe you're ready to expand your reach, or perhaps it's time to consider your legacy and the future of your business. Either way, it all begins with a conversation. Schedule a confidential, no-obligation call to explore what the future might hold for you and your business.
Complete the form, and we'll reach out for a chat...
© 2025 SENATE HEALTHCARE LLC.
ALL RIGHTS RESERVED
